Trial Profile
A Double Blind, Randomized, Placebo-Controlled Study of CM-AT for the Treatment of Autism in Children With All Levels of Fecal Chymotrypsin (FCT)
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 28 Oct 2022
Price :
$35
*
At a glance
- Drugs CM 4612 (Primary)
- Indications Autistic disorder
- Focus Registrational; Therapeutic Use
- Acronyms Blum Study
- Sponsors Curemark
- 06 May 2019 Results published in the Media Release
- 06 May 2019 According to a Curemark media release, data from the study were presented at the International Society of Autism Research (INSAR) Annual Meeting 2019. The presentation focused on data from the preschool population included in the study.
- 21 Mar 2018 Status changed from active, no longer recruiting to completed.